title: New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.
abstract: Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM, ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM.
authors: Departments of Pathology and Human Oncology & Pathogenesis Program, Surgery, and Cell Biology Program, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.
authors: Marc
authors: M
authors: Ladanyi
authors: Marjorie G
authors: MG
authors: Zauderer
authors: Lee M
authors: LM
authors: Krug
authors: Tatsuo
authors: T
authors: Ito
authors: Robert
authors: R
authors: McMillan
authors: Matthew
authors: M
authors: Bott
authors: Filippo
authors: F
authors: Giancotti
mesh_terms: D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006801:Humans; D008654:Mesothelioma / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D058990:Molecular Targeted Therapy; D016518:Neurofibromatosis 2 / Q000235:genetics / Q000378:metabolism; D018570:Risk Assessment; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism; D043222:Ubiquitin Thiolesterase / Q000235:genetics / Q000378:metabolism
chemical_list: C400134:BAP1 protein, human; D025521:Tumor Suppressor Proteins; D043222:Ubiquitin Thiolesterase